Floatz logo

Bb-Mpi-03

Triple-negative Breast Cancer

Sellas Life Sciences Groupprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the Triple-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
utd1
Fudan University
Phase 3B
Lornoxicam
Fudan University
Phase 3B
Tucidinostat
wang shusen
Phase 2B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
AstraZeneca
Phase 2B
Durvalumab
AstraZeneca
Phase 2B

View all 50 →

Same molecule, other indications

Bb-Mpi-03 is also rated in:

Acute Myeloid LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Acute Lymphoblastic LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Ovarian CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →